MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
KAT6A Syndrome: genotype-phenotype correlation in 76 patients with pathogenic KAT6A variants.
|
30245513 |
2019 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay.
|
25728775 |
2015 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay.
|
25728775 |
2015 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Dominant mutations in KAT6A cause intellectual disability with recognizable syndromic features.
|
25728777 |
2015 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
Dominant mutations in KAT6A cause intellectual disability with recognizable syndromic features.
|
25728777 |
2015 |
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
MENTAL RETARDATION, AUTOSOMAL DOMINANT 32
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
|
29662167 |
2018 |
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.
|
29662167 |
2018 |
Adenoid Cystic Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
The mutational landscape of adenoid cystic carcinoma.
|
23685749 |
2013 |
Acute myeloid leukemia with t(8;16)(p11;p13) translocation
|
0.300 |
FusionGene
|
disease |
ORPHANET |
Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.
|
23974201 |
2013 |
Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
19270706 |
2009 |
Medullomyoblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
19270706 |
2009 |
Childhood Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
19270706 |
2009 |
Adult Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
19270706 |
2009 |
Desmoplastic Medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
19270706 |
2009 |
Melanotic medulloblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma.
|
19270706 |
2009 |
Acute myeloid leukemia with t(8;16)(p11;p13) translocation
|
0.300 |
FusionGene
|
disease |
ORPHANET |
Two novel variants of MOZ-CBP fusion transcripts in spontaneously remitted infant leukemia with t(1;16;8)(p13;p13;p11), a new variant of t(8;16)(p11;p13).
|
18698081 |
2008 |
DiGeorge Syndrome
|
0.200 |
Biomarker
|
disease |
MGD |
Here we show that lack of the histone acetyltransferase MOZ (MYST3/KAT6A) phenocopies DiGeorge syndrome, and the MOZ complex occupies the Tbx1 locus, promoting its expression and histone 3 lysine 9 acetylation.
|
22921202 |
2012 |
Liver Neoplasms, Experimental
|
0.200 |
Biomarker
|
phenotype |
RGD |
Histone acetyltransferase MOZ acts as a co-activator of Nrf2-MafK and induces tumour marker gene expression during hepatocarcinogenesis.
|
17083329 |
2007 |
DiGeorge Syndrome
|
0.200 |
Biomarker
|
disease |
MGD |
Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells.
|
16651658 |
2006 |
Global developmental delay
|
0.130 |
Biomarker
|
disease |
BEFREE |
Pathogenic variants in KAT6A have recently been identified as a cause of syndromic developmental delay.
|
30245513 |
2019 |
Global developmental delay
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
A KAT6A variant in a family with autosomal dominantly inherited microcephaly and developmental delay.
|
29899504 |
2018 |